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Now 30 years old, the chronic mild stress (CMS) model of depression has been used in >1300 published
studies, with a year-on-year increase rising to >200 papers in 2015. Data from a survey of users show
that while a variety of names are in use (chronic mild/unpredictable/varied stress), these describe
essentially the same procedure. This paper provides an update on the validity and reliability of the CMS
model, and reviews recent data on the neurobiological basis of CMS effects and the mechanisms of
antidepressant action: the volume of this research may be unique in providing a comprehensive account
of antidepressant action within a single model. Also discussed is the use of CMS in drug discovery, with
particular reference to hippocampal and extra-hippocampal targets. The high translational potential of
the CMS model means that the neurobiological mechanisms described may be of particular relevance to
human depression and mechanisms of clinical antidepressant action.
© 2016 The Author. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Contents
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Animal models of psychiatric states are procedures applied to
laboratory animals which engender behavioural changes that areInc. This is an open access article
The chronic mild stress (CMS
tr.2016.08.002intended to be homologous to aspects of psychiatric disorders, and
can therefore be used as experimental tools to further the under-
standing of human psychopathology (Willner, 2009). The chronic
mild stress (CMS)model of depression (Willner et al., 1992;Willner,
1997) is often considered as a prototypical example. In this model,
rats or mice are exposed chronically to a constant bombardment ofunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
) model of depression: History, evaluation and usage, Neurobiology of
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plethora of behavioural changes, including decreased response to
rewards, a behavioural correlate of the clinical core symptom of
depression, anhedonia. In the canonical version of the model,
reward sensitivity is tracked by periodic tests inwhich the animal is
given access to a highly preferred sweet solution, or to a choice
between a sweet solution and plain water. Consumption of, or
preference for, the sweet reward decreases over weeks of exposure
but can be restored to normal levels by chronic treatment with
antidepressant drugs.
This paper presents a historical overview of the CMS model,
considers some areas of controversy, and reviews recent research in
three major areas of application: neurobiological processes medi-
ating the effects of chronic stress, cellular and systemic mecha-
nisms of antidepressant action, and antidepressant drug discovery.
The focus of the review is on the speciﬁc contributions of CMS
research, rather than an integration of CMS studies with the wider
literature. The aim, in taking this approach, was to explore how
comprehensive a story this single model provides.
2. Origins
The origin of the CMSmodel was in series of studies by Katz and
colleagues, published in the early 1980s, in which rats were
exposed sequentially to a variety of severe stressors. Most of these
studies assessed the effects of stress using changes in open ﬁeld
behaviour, which were reported to be reversed speciﬁcally by
chronic treatment with antidepressant drugs, but not by non-
antidepressants (e.g. Katz and Hersch, 1981; Katz et al., 1981a,b;
Katz and Baldrighi, 1982). However, in one study, it was observed
that animals exposed to the chronic stress regime failed to increase
their ﬂuid consumption when saccharin or sucrose were added to
their drinking water, and it was postulated that this might reﬂect a
decrease in the hedonic impact of the sweetener (Katz, 1982). This
hypothesis was supported by the demonstration by Anisman and
colleagues that uncontrollable footshock can lead to impairments
of behaviour maintained by brain stimulation reward (Zacharko
et al., 1983, 1984). The importance of anhedonia (the decreased
ability to experience pleasure) as a core symptom of depression,
both then and now (American Psychiatric Association, 2013),
stimulated research to develop and validate a model of stress-
induced anhedonia as a tool, initially, to study the mechanisms of
antidepressant action.
In addition to making hedonic measures the primary focus of
the model, a second change to the procedure described by Katz and
colleagues was that the severity of the stressors employed was
greatly reduced. This change was made for ethical reasons, and in
the context of the Animals (Scientiﬁc Procedures) Act (1986) that
had very recently tightened the framework for animal research in
the UK, placing an emphasis on minimizing stress wherever
possible. Consequently, the CMS regime as initially developed did
not include any of the severely stressful elements used by Katz and
colleagues, such as intense footshock, cold water immersion, or
prolonged (48 h) food and water deprivation. The birth of the CMS
procedure was in a lab meeting in 1986 where those present
brainstormed the problems that might arise if animals were
curated by a thoroughly incompetent technician: water bottles
might leak into the bedding; it might not be noticed that food and
water supplies needed replenishment; the light-dark cycle in the
animal house, and the lights themselves, might malfunction;
housing conditions might change unpredictably; the environment
might be noisy; and so on. All of the ideas generated were then
implemented in a combination that was unremitting (no stress-free
periods) and continuous over many weeks (the chronic element of
CMS). For licensing purposes under the 1986 Act, all of thePlease cite this article in press as: Willner, P., The chronic mild stress (CMS
Stress (2016), http://dx.doi.org/10.1016/j.ynstr.2016.08.002individual micro-stressors were considered to be ‘mild’ but the
overall procedure was given a ‘moderately stressful’ banding. The
ﬁrst publication using the CMS procedure reported that rats
exposed chronically (5e9 weeks) to CMS, and tested weekly,
showed a reduced consumption of, and preference for, weak solu-
tions of saccharin or sucrose, which developed over the course of
several weeks exposure, and that the decreased sucrose preference
was restored by 2e4 weeks of treatment with a tricyclic antide-
pressant (Willner et al., 1987).
Over the next few years, this observation was extended to other
typical and atypical antidepressants (e.g. Muscat et al., 1992; Cheeta
et al., 1994; Papp et al., 1996), and the behavioural effects of CMS
were more fully characterized (e.g. Muscat and Willner, 1992;
D'Aquila et al., 1994; Cheeta et al., 1997), in particular by the
observation that behavioural changes compatible with anhedonia
were seen not only in consumption tests but also using place
preference conditioning methods (e.g. Papp et al., 1991, 1992), and a
comparable CMS procedure was implemented in mice (Monleon
et al., 1994). This period also saw the ﬁrst use of the CMS model
to study brain mechanisms underlying antidepressant action, with
a particular focus at that time on the mesolimbic dopamine system,
which had been somewhat overlooked in earlier depression
research (e.g. Stamford et al., 1991; Papp et al., 1994; Dziedzicka-
Wasylewska et al., 1997), suggesting a novel direction for antide-
pressant drug development (e.g. Muscat et al., 1992; Willner et al.,
1994). Other labs began to take up the CMS procedure, with a
particularly important contribution by Moreau et al. (1992, 1993)
who reported that CMS-induced anhedonia, and its reversal by
chronic antidepressant treatment, could also be demonstrated as a
change in the threshold for intracranial self-stimulation of the
ventral tegmental area. A 1997 review of the ﬁrst ten years of CMS
research identiﬁed 12 additional labs that were working with the
CMS as applied to rats, half of which had not yet reached the stage
of refereed publication, as well as one other lab working with mice
(Willner, 1997).
3. Uptake
From those beginnings, there has been an exponential growth in
the number of laboratories and publications using the CMS pro-
cedure, amounting, in 2015 alone, to 230 publications from 180 labs
in more than 30 countries (Fig. 1). From the ﬁgures shown in Fig. 1,
it can be estimated that by the end of 2015 well in excess of 1300
papers using this methodology had been published. The
geographical origins of CMS publications are shown in Fig. 2. It can
be seen that in addition to the growth in the number of publica-
tions, the centre of gravity has shifted from a predominantly Eu-
ropean activity in 2000 to a predominance of Chinese publications,
amounting to greater than 50% of the total in 2015.
With the exception of two studies in ﬁsh, the 230 papers pub-
lished in 2015 all concerned studies in rats or mice. In order to gain
an overview of the scientiﬁc focus of CMS studies, these 230 papers
were classiﬁed, on the basis of the abstract, into three categories:
Neuroscience, where the paper included direct measures of brain
structure, function or constituents; Other, which comprised studies
of stress effects on behaviour or on physiological systems other
than the brain, including tests of putative antidepressant agents;
and Traditional medicine, which included any publication with a
focus on plant-derived or other natural products as well as pro-
cedures such as acupuncture, irrespective of the other content of
the paper (that is, the Traditional medicine category over-rode the
other two categories). Table 1 shows the number and proportion of
each type of investigation in different geographical regions. The
predominant focus in the western world (Europe and North
America) is neuroscientiﬁc, while over a third of Chinese) model of depression: History, evaluation and usage, Neurobiology of
Fig. 1. Uptake of the CMS model: 1990e2015.
Fig. 2. Geographical origin of CMS studies. The size of the circle approximates the volume of publications in each year.
Table 1
Distribution of CMS studies in 2015.
Number in 2015a Proportions
N O T Total %N %O %T
Europe 26 8 0 34 76 24 0
North America 24 10 0 34 71 29 0
China 60 16 42 118 51 14 36
Rest of world 20 22 2 44 45 50 5
a Publications are coded as: involving traditional medicine products or proced-
ures, including studies of their neurobiological basis (T); other studies with a
neurobiological focus (N); and other non-neurobiological studies: for example, use
in drug discovery (O).
Table 2
Proportion of labs using random stressor presentation.
Unpredictable? Overall Mice Rats
No (CMS/CVS) 61% 87% 48%
Yes (CUMS/UCMS/UCS) 87% 92% 86%
p ¼ 0.009 p ¼ 0.036
p ¼ Fisher exact probability test.
P. Willner / Neurobiology of Stress xxx (2016) 1e16 3investigations are focussed on traditional medicine: however, 78%
of the non-Traditional Chinese studies were classiﬁed as neuro-
science, similar to western studies. This proportion was somewhat
smaller in ‘rest of world’ countries, of which Brazil and India were
the most proliﬁc (11 and 8 publications from 8 to 7 labs
respectively).
4. What's in a name?
Although in this paper the model under discussion is referred to
generically as CMS, the literature reviewed covers a range of
ostensibly different procedures with the common feature that they
involve chronic administration of a variety of different stressors. An
accompanying paper (Willner, 2016) describes a survey of users of
these procedures (as discussed further below). Respondents to thePlease cite this article in press as: Willner, P., The chronic mild stress (CMS
Stress (2016), http://dx.doi.org/10.1016/j.ynstr.2016.08.002survey variously described their procedure as chronic mild stress
(CMS, n ¼ 26), chronic unpredictable stress (CUS or UCS, n ¼ 11),
chronic unpredictable mild stress (CUMS or UCMS, n ¼ 25), or
chronic variable stress (CVS, n ¼ 9). This raises the question of
whether the different names do in fact denote different procedures:
speciﬁcally, whether the term ‘Unpredictable’ denotes that the
procedure is more random, and whether the term ‘Mild’ denotes
that the procedure is less severe, than when these terms are not
used.
The question of predictability is easily addressed by interro-
gating the survey responses with respect to whether the micro-
stressors making up the stress regime were presented in a ﬁxed
order fromweek to week, or randomly. (It is questionable whether
rodents would be able to discern the regularity in a pattern of
stressors encountered at weekly intervals, but many labs use
random scheduling as a precaution.) The survey received a total of
71 responses, with a roughly equal representation of rat and mouse
labs. The majority of labs (75%) employed random presentation,
with a marginally greater usage with mice than with rats (85% vs.) model of depression: History, evaluation and usage, Neurobiology of
P. Willner / Neurobiology of Stress xxx (2016) 1e16466%, p ¼ 0.049). Table 2 summarizes usage of the term ‘Unpre-
dictable’ in relation to random vs. ﬁxed stressor presentation.
Overall, a procedure designated as ‘Unpredictable’ is more likely to
use random stressor presentation. However, while marginally sig-
niﬁcant for rats, this relationship is absent for mice because ﬁxed
stressor presentation is so rarely used with mice. Thus, the term
‘Unpredictable’ does not add meaning when applied to mouse
studies. And while the term is to some extent meaningful when
applied to rat studies, almost half of rat studies that were not
designated as ‘Unpredictable’ nevertheless used random stressor
presentation.
The question of severity is more recondite, because the relative
severity of different stress procedures is uncertain in the absence of
comparative physiological data. To address this issue, the different
micro-stressors included in CMS-type studies were each rated for
severity, on a 5-point scale, using an expert consensus procedure
described in the accompanying paper (Willner, 2016), and these
ratings were used to construct three crude severity indices for each
of the chronic stress procedures in the database: variety (the
number of micro-stressors applied), severity (the proportion of
micro-stressors rated 4 or 5 on the 5-point severity scale), and
burden (the total of all ratings). The scores on these three measures
are shown in Table 3, separately for rats and mice, for those pro-
cedures that were described as ‘Mild’ (CMS, UCMS) and those that
were not (CUS, CVS). None of the comparisons differ signiﬁcantly.
As an aside, it has been claimed that the CUS and UCMS procedures
differ in that the former has “the advantage of … the absence of
stressors that interfere with water and/or food deprivation”
(Monteiro et al., 2015). In fact, the opposite appears to be the case:
of the 12 labs in the survey that described their procedure as CUS,
10 include water and/or food deprivation in the stress schedule
(83%), compared with only 16 of the 25 (64%) that described their
procedure as UCMS.
Wemay conclude from this analysis that the name by which the
stress regime is described contains almost no information. With a
single modest exception (presentation order in rats) the use, or
non-use, of the terms Mild and Unpredictable has no discernible
relationship to the content of these stress schedules. The content of
the schedules is highly variable, but not in a manner that is re-
ﬂected in the names by which they are described. Therefore, the
differently designated procedures have been treated as equivalent
for the purposes of this review.5. Validity
The validity of animal models of psychiatric disorders is usually
assessed using a multidimensional approach in which a model is
evaluated in respect of its predictive validity (performance in the
test predicts performance in the condition being modelled), face
validity (there are phenomenological similarities between the two),
and construct validity (themodel has a sound theoretical rationale).Table 3
Estimates of stress severity in relation to whether a stress procedure is described as
“mild” a.
Mice Rats
Mild? Yes No Yes No
n 24 6 23 12
Variety 7.08 (0.35) 7.50 (0.76) 7.41 (0.38) 7.25 (0.46)
Severity 40.4 (3.5) 39.3 (5.3) 26.5 (2.5) 38.0 (5.4)
Burden 21.0 (1.2) 21.8 (2.6) 20.1 (1.1) 21.8 (1.5)
a Values are mean (standard error) For this analysis, six response were excluded
where respondents reported using both mice and rats, because it was uncertain
whether the stress regime reported was applied to one species or to both.
Please cite this article in press as: Willner, P., The chronic mild stress (CMS
Stress (2016), http://dx.doi.org/10.1016/j.ynstr.2016.08.002In relation to animal models of depression, predictive validity refers
primarily to speciﬁc and selective responsiveness to (drug and non-
drug) antidepressants; face validity is assessed by comparison to
DSM (now DSM-V) symptom checklists, with particular reference
to core symptoms of depression; and construct validity is based on
an argument for similarity of psychological constructs, such as
responsiveness to rewarding events, or if they are known, the un-
derlying neurobiological mechanisms. These principles were ﬁrst
proposed in relation to animal models of depression (Willner, 1984)
and the CMS model was the ﬁrst model to be systematically
investigated using this framework, as summarized in a review of
the ﬁrst ten years of CMS research (Willner, 1997).
Regarding its predictive validity, the CMS model was shown in
early research to respond to chronic, but not acute, administration
of a wide range of established antidepressant drugs (and to elec-
troconvulsive shock), but not to drugs that are clinically ineffective
as antidepressants (summarized in Willner, 1997, Table 2). Over the
subsequent decades, the pharmaceutical industry has been
remarkably unsuccessful in its attempts to bring new and improved
antidepressants to the clinic. A few notable exceptions are the very
selective SSRI escitalopram, the dual 5-HT/noradrenaline uptake
inhibitor venlafaxine, and the 5HT2C/melatonin agonist agomela-
tine: all of these newer drugs are also effective in the CMS model
(Montgomery et al., 2001; Millan et al., 2001; Papp et al., 2003).
Also effective are experimental antidepressant strategies that are
showing promising results in clinical investigations, including re-
petitive transcranial magnetic stimulation (e.g. Feng et al., 2012;
Wang et al., 2014), deep brain stimulation (e.g. Hamani et al.,
2012; Dournes et al., 2013; Lim et al., 2015) and the NMDA gluta-
mate antagonist ketamine (e.g. Garcia et al., 2009; Ma et al., 2013;
Papp et al., 2016a).
An attractive feature of the CMS model is the range of behav-
ioural and physiological changes seen following exposure to CMS
that parallel symptoms of depression, supporting the face validity
of the model. The 1997 review considered the sequelae of CMS in
relation to the DSM-IV diagnoses of major depression and melan-
cholia (major depressionwithmelancholic features), diagnoses that
are almost unchanged in DSM-V (American Psychiatric Association,
2013). The effects of CMS include, in addition to anhedonia-like
impairments in tests of rewarded behaviour, decreases in the per-
formance of other motivated (e.g. sexual and aggressive) behav-
iours, relative weight loss (i.e., a slower rate of weight gain),
disrupted sleep patterns, decreased locomotor activity, and
decreased “active waking” in the EEG, all of which parallel symp-
toms of major depression, as well speciﬁc characteristics of
melancholia, such as worsening in the early part of the waking
phase and a phase advance of circadian rhythms (summarized in
Willner, 1997, Table 1). Indeed, it was argued in the 1997 review
that “the only symptoms of depression that have not been
demonstrated in animals exposed to CMS are those uniquely hu-
man symptoms that are only accessible to verbal enquiry” and that
by applying the DSM diagnostic rules, “a rat exposed to CMS could,
in principle, legitimately attract a DSM-IV diagnosis of either major
depressive disorder or major depressive disorder with melancholic
features” (Willner, 1997, p.323). Setting aside subjective symptoms
such as suicidal ideation that in principle cannot be modelled in
animals, there was a single piece missing from the picture: at that
time, no parallel had been demonstrated in CMS studies to the
clinical symptom of “diminished ability to think or concentrate or
indecisiveness”. This gap was subsequently ﬁlled by a substantial
literature demonstrating cognitive impairments following CMS, in
tests as diverse as spatial learning (e.g. Song et al., 2006; Cuadrado-
Tejedor et al., 2011) and novel object recognition (e.g. Orsetti et al.,
2007; Elizalde et al., 2008). One change from DSM-IV to DSM-V is
the recognition in DSM-V that depression may be associated with) model of depression: History, evaluation and usage, Neurobiology of
P. Willner / Neurobiology of Stress xxx (2016) 1e16 5high levels of anxiety (denoted by the speciﬁer “with anxious
distress”). While not universally observed, anxiogenic effects, have
frequently been described in animals subjected to CMS (e.g. Surget
et al., 2008; Wang et al., 2014; Papp et al., 2016a,b). Like the
anhedonic effects, CMS-induced cognitive impairments and anx-
iogenesis are also reversed by chronic antidepressant treatment.
Broadly speaking, theories of depression have either a psycho-
logical or a neurobiological basis (though there are recent attempts
to bring these two explanatory frameworks into alignment: e.g.
Disner et al., 2011; Willner et al., 2013). Hence there are two routes
to construct validity for an animal model of depression. The theo-
retical rationale for the CMS model from a psychological perspec-
tive is that this procedure simulates anhedonia, a loss of
responsiveness to pleasant events. This rationale rests on two as-
sumptions, that sucrose drinking is a valid measure of sensitivity to
reward, and that CMS causes a generalized decrease in reward
sensitivity, rather than a speciﬁc effect on responses to sweet tastes.
The second of these assumptions is uncontroversial: as mentioned
earlier, in addition to a decreased response to sweet tastes, CMS
also increases the threshold for brain stimulation reward (e.g.
Moreau et al., 1992, 1993) and impairs the formation of condi-
tioning place preferences to a wide variety of natural or drug re-
inforcers (e.g. Papp et al., 1991, 1992). The ﬁrst assumption was
challenged by two early reports that decreased sucrose consump-
tion was secondary to a loss of body weight (Matthews et al., 1995;
Forbes et al., 1996). However, this critique was comprehensively
refuted by many studies demonstrating that decreased sucrose
intake or preference could be observed in the absence of body
weight loss (including studies that excluded food and water
deprivation from the CMS regime), or after taking body weight loss
into account (Willner et al., 1996; Willner, 1997; for a recent
example: Papp et al., 2016a.b). A further indication that changes in
sucrose intake or preference are not secondary to body weight loss
is that chronic antidepressant treatment normalizes the hedonic
measures but typically does not restore body weight (Willner,
1997). It was also noted that the procedure used in the studies
that gave rise to this critique were associated with extreme (>20%)
loss of body weight relative to non-stressed controls, and that the
results reported may reﬂect the stress associated with the pro-
cedure used to induce weight loss, rather than weight loss per se
(Willner, 1997). A more recent point of criticism is that despite their
pervasive anhedonia, while depressed patients sometimes report
that sweet tastes are less pleasant (e.g. Steiner et al., 1993), more
typically they do not (e.g. Dichter et al., 2010). However, “taste”
reactivity includes an olfactory component, which is likely to be a
much larger factor in rodents, given their greater olfactory sensi-
tivity relative to humans: interestingly, while depressed people
may not show taste anhedonia, they do show olfactory anhedonia
(Atanasova et al., 2010; Naudin et al., 2012, 2014). The relative
contributions of gustatory and olfactory inputs to the decreased
response to sweet tastes in rodents exposed to CMS remains to be
established. It may also be relevant to note that a sucrose-drinking
session represents a greater source of reward for rodents (relative
to other ongoing life experiences) than a human taste test.
The explosion of CMS research (Fig. 2), and the predominance of
studies with a primarily neuroscientiﬁc focus (Table 1), has resulted
in an extensive literature exploring parallels between the physio-
logical mechanisms underlying CMS effects and clinical depression.
A systematic review of neurochemical studies published up to 2010
concluded that CMS reliably affects “neurobiological variables that
exhibit coincident alterations in clinical populations with major
depressive disorder… (including)… upregulation of frontocortical
5-HT2A receptors, downregulation of hippocampal 5-HT1A re-
ceptors, upregulation of cortical b-adrenoreceptors, down-
regulation of hippocampal GR, increases in CRH mRNA in the PVNPlease cite this article in press as: Willner, P., The chronic mild stress (CMS
Stress (2016), http://dx.doi.org/10.1016/j.ynstr.2016.08.002of the hypothalamus, upregulation of prefrontal cortical cannabi-
noid CB1 receptors, reductions in frontocortical and hippocampal
BDNF protein and reductions in cortical AC-PKA signalling” (Hill
et al., 2012, p.2110). There are also morphological parallels be-
tween CMS and depression: in particular, the major structural
change that is reliably reported in the depressed brain is a decrease
in the volume of the hippocampus (Campbell et al., 2004; Videbech
and Ravnkilde, 2004), an effect that is also associated with CMS-
induced anhedonia (Delgado y Palacios et al., 2011; Luo et al.,
2014). As outlined below, studies using the CMS model have
made a major contribution to the construction of a theoretical ac-
count of psychobiological processes in depression and antidepres-
sant action (Willner et al., 2013), further strengthening the
construct validity of the model.
6. Reliability
The chronicmild stress (CMS) model of depression is considered
by many to be the animal model of depression that has the greatest
validity and translational potential, but it has often been criticized
for a perceived lack of reliability. Indeed, the view that the pro-
cedure is unreliable is widely accepted, and features prominently in
reviews of animal models of depression (see Willner, 2016 for ex-
amples). However, this position is difﬁcult to reconcile with the fact
that the CMS model has been used successfully in, literally, hun-
dreds of laboratories worldwide (see Fig. 1). The study reported in
the accompanying paper (Willner, 2016) was undertaken to explore
this discrepancy, with the aims of establishing the extent to which
the CMS model is reproducible, and identifying experimental var-
iables relevant to its reliability. Because failures to replicate
frequently remain unpublished, a survey methodology was used. A
questionnaire was circulated to 170 labs identiﬁed from a PubMed
search as having published a CMS study in the years 2010 or 2015.
No selection was applied in respect of the results reported, and
recipients were guaranteed anonymity in order to encourage
honest reporting of difﬁculties they may have experienced.
Responses were returned by 71 (42%) of the recipients, followed
by further correspondence with some of them. Most of the re-
spondents (n ¼ 53: 75%) reported that the CMS procedure worked
reliably in their hands. Of the others, 15 (21%) reported that the
procedure was usually reliable, though not always (n ¼ 9: 13%) or
not for all measures (n ¼ 6: 8%). Only three respondents (4%) re-
ported being unable to reproduce the characteristic effects of CMS,
two of whom may be using an insufﬁcient duration of CMS expo-
sure. The study has the obvious limitation that it was not possible to
include laboratories that may haveworkedwith the CMSmodel but
not published their data. However, the overwhelming message
from a large sample is that the CMS model does appear to be
generally reliable within laboratories and robust across labora-
tories. Consequently, it appears that the many published state-
ments to the effect that the procedure is unreliable are incorrect.
A series of analyses compared the 75% of ‘reliable’ labs with the
25% of ‘less reliable’ labs on a range of experimenter, subject, stress
and outcome variables. Few if any signiﬁcant differences between
these two samples were identiﬁed, possibly because of the small
size and diversity of the ‘less reliable’ sample. Consequently, the
study did not succeed in identifying the critical features of the CMS
procedure that result in a less effective implementation in a mi-
nority of laboratories. However, from an overview of the survey
responses and the published literature, it appears that success with
using the model depends on an interplay between (i) individual
differences in susceptibility to stress, both within and between
animal populations, (ii) the overall severity of the micro-stressors
applied, which need to be sufﬁciently intense to evoke a physio-
logical stress response and sufﬁciently variable to prevent) model of depression: History, evaluation and usage, Neurobiology of
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practices, which are particularly important when the sucrose test is
used as the main outcome measure. The evidence underpinning
these conclusions is presented in the accompanying paper (Willner,
2016).
7. Individual differences in susceptibility to CMS
Of all the factors that have been studied in relation to the reli-
ability of the CMS model, individual differences have received the
greatest attention. Individual differences in susceptibility to CMS
have been studied in relation to strain differences, ‘personality’
characteristics, genomic manipulations and natural variation.
The best characterized strain difference is between the more
resilient C57BL/6 and more susceptible BALB/c mouse strains
(Grifﬁths et al., 1992; Ducottet and Belzung, 2004, 2005; Farley
et al., 2012; Palumbo et al., 2010). Increased susceptibility to CMS
has also been reported for Flinders Sensitive Line rats relative to the
Flinders Resistant Line (Pucilowski et al., 1993), while DBA/2 mice
are more even more resilient than C57BL/6 mice (Pothion et al.,
2004). This variability in the response to CMS reﬂects strain dif-
ferences in anxiety- and depression-relevant behaviours: greater
susceptibility to CMS, both between and within strains, has been
found to be associated with high levels of anxiety in both rats and
mice (Ducottet et al., 2004; Ducottet and Belzung, 2005; Li et al.,
2010; Castro et al., 2012), emotionality in rats (Stedenfeld et al.,
2011), and submissiveness in mice (Strekalova et al., 2004, 2011).
There are also anxiety-related differences in susceptibility to CMS
among outbred Wistar rats from different suppliers, which could
result from genetic drift, different rearing conditions, or a combi-
nation of these two factors (Theilmann et al., 2016).
Genomic manipulations have been reported that increase both
susceptibility and resilience to CMS. For example, a knockout of the
cannabinoid CB1 receptor increased susceptibility to CMS (Valverde
and Torrens, 2012), consistent with preclinical and clinical evidence
of a protective role of cannabinoid neurotransmission in depression
(Gorzalka and Hill, 2011). Conversely, overexpression of the
cannabinoid CB2 receptor conferred resilience to CMS (García-
Gutierrez et al., 2010), albeit that pharmacological manipulations
of the CB2 receptor failed to alter sucrose intake after CMS in BALB/
c mice (Onaivi et al., 2008). Other genomic variants that increase
susceptibility to CMS in mice include knockdown of the VGLUT1
receptor, which leads to increased glutamate and decreased GABA
levels in the cortex and hippocampus (Garcia-Garcia et al., 2009),
and an OCT2 null mutant, which displays an enhanced HPA
response to stress (Courousse et al., 2014). Conversely, several
genomic over-expression models present increased resilience to
CMS. These include rats that over-express the signal transduction
factor ERK2, causing a decrease in the ﬁring of dopamine cells in the
ventral tegmental area (I~niguez et al., 2010), and rats that over-
express brain-derived neurotrophic factor (BDNF) in the hippo-
campus (Taliaz et al., 2011), two systems that are strongly impli-
cated in the behavioural effects of CMS, as described below.
Resilience is also shown by mice with over-expression of mineral-
ocorticoid receptors in the hippocampus (Kanatsou et al., 2015),
which dampens the HPA response to stress (de Kloet et al., 2016).
There is increasing interest in examining neurochemical differ-
ences between subgroups of susceptible and resilient rats (Wiborg,
2013) and mice (Strekalova and Steinbusch, 2010) deﬁned empiri-
cally by their behavioural response to CMS. A gene proﬁling study
identiﬁed several hundred genes that were differently regulated in
mice characterized as vulnerable or resilient to CMS (Strekalova
et al., 2011). Similar patterns of gene expression (Christensen
et al., 2011) and protein expression (Bisgaard et al., 2007) were
observed between animals that were resilient to CMS, and thosePlease cite this article in press as: Willner, P., The chronic mild stress (CMS
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pressant treatment; these two groups differed in gene and protein
expression from animals that developed anhedonia but were
treatment-resistant. Proteomic studies have found that susceptible
and resilient animals differ, inter alia, in presynaptic proteins
involved in neurotransmitter release (Bisgaard et al., 2007;
Henningsen et al., 2012; Han et al., 2015) and in levels of neuro-
trophins, which were decreased in CMS-susceptible animals and
increased in resilient animals (Bergstr€om et al., 2008; Farhang et al.,
2014). The neurochemical results are not entirely consistent,
however: for example, an increased expression of the 5HT trans-
porter has been associated with both susceptibility (Couch et al.,
2013) and resilience (Tang et al., 2013) to CMS.
Because CMS-susceptible and CMS-resilient animals are iden-
tiﬁed post hoc, it can be difﬁcult to determine whether differences
between these populations, and between these subgroups and
non-stressed animals, represent trait-like individual differences
that could play a causal role in the differential behavioural
response, or consequences of CMS exposure. For some ﬁndings, the
neurochemical differences appear consequential to CMS. For
example, Zurawek et al. (2013) reported that both stress-
susceptible and stress-resilient rats showed a down-regulation of
dopamine D2 receptors when exposed to CMS, but with continued
exposure D2 receptor density recovered to control levels in resilient
animals, while remaining low in susceptible animals. In some other
studies, neurochemical parameters that distinguished susceptible
and resilient animals were reported to equalize in CMS-susceptible
animals that responded to antidepressant treatment (Tang et al.,
2013; Li et al., 2014; Nieto-Gonzalez et al., 2015), again, suggest-
ing that the differences reﬂect consequences of CMS rather than
trait-like predisposing factors. Other ﬁndings suggest a more trait-
like difference. For example, CMS-susceptible animals showed a
decrease in enkephalin mRNA expression in the basolateral
amygdala, which was not seen in CMS-resilient animals. The trait-
like nature of this difference is suggested by the further observation
that the effect of CMSwasmimicked by a knockdown of enkephalin
in the basolateral amygdala (Berube et al., 2014). These examples
illustrate the difﬁculty of interpreting studies of empirically deﬁned
vulnerable vs. resilient animals, and the need for further investi-
gation to clarify experimental ﬁndings.
8. Brain mechanisms underlying the effects of CMS
As described above, there has been extensive research on the
physiological changes seen in the brains of rats and mice subjected
to CMS, and a comprehensive review of this literature described
how the effects of CMS on numerous neurochemical systems
closely parallel the neurochemical abnormalities described in the
brains of depressed patients (Hill et al., 2012). But what initiates
these changes? There is a clear answer to this question: perhaps
unsurprisingly, the effects of CMS reﬂect an elevated physiological
stress response.
The major stress-responsive system is the hypothalamus-
pituitary-adrenal (HPA) axis. The critical role of this system in the
effects of CMS is demonstrated by experiments showing that the
development of a depressive phenotype during exposure to CMS
(decreased sucrose preference and other typical behavioural
changes) is blocked by the glucocorticoid receptor antagonist
mifepristone (Wu et al., 2007), the corticosterone synthesis inhib-
itor metyrapone (Kvarta et al., 2015) or adrenalectomy (Goshen
et al., 2008; Chen et al., 2016). Conversely, the behavioural and
physiological effects of CMS can be mimicked by chronic exogenous
administration of corticosterone (Goshen et al., 2008; Gourley and
Taylor, 2009; Kvarta et al., 2015), demonstrating that elevated ac-
tivity of the HPA axis is both necessary and sufﬁcient for the) model of depression: History, evaluation and usage, Neurobiology of
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levels of corticosterone (e.g. Goshen et al., 2008; Kvarta et al., 2015;
and numerous other studies) there are also many reports of CMS
inducing anhedonic and other depressive-like behaviours in the
absence of a detectable elevation of plasma corticosterone (e.g.
Willner et al., 1987; Remus et al., 2015; for ancient and modern
examples). This probably reﬂects the fact that corticosterone spikes
are elicited in response to the onset of each individual stressor
(Sapolsky et al., 1984; Magarinos et al., 1996), making the timing of
corticosterone assays critical. The difference between CMS, which
induces anhedonia, and repeated administration of the same
stressor, which typically does not (e.g. Zhu et al., 2014) is that under
repeated presentation of the same stressor, HPA activity habituates,
whereas under CMS the acute HPA response to each novel stressor
remains intact (e.g. Radley and Sawchenko, 2015).
The systemic mechanisms by which CMS-induced HPA activa-
tion results in behavioural impairments are also now reasonably
well understood. The critical factor is that HPA activity is held in
check by negative feedback systems operating through forebrain
structures, with the primary feedback at the level of the hippo-
campus (Jacobson and Sapolsky, 1991; Herman et al., 1996; Belzung
and Billette de Villemeur, 2010). However, chronic exposure to
glucocorticoids is neurotoxic, and hippocampal granule cells are
particularly sensitive to these effects, leading to a loss of the
inhibitory effect of the hippocampus on HPA activity. Effects of CMS
exposure on the hippocampus include an initial activation of
microglia, a hallmark of neuropathology, which is probably driven
by increased exposure to glucocorticoids (Walker et al., 2013): a
causative role of this effect is suggested by the fact that minocy-
cline, which blocks microglial activation, also prevents the later
development of CMS-induced anhedonia (Kreisel et al., 2014). More
prolonged exposure to CMS causes a decreased hippocampal
expression of the nuclear transcription factor CREB, leading to
decreased expression of BDNF (Grønli et al., 2006; Song et al., 2006)
and other neurotrophins (Warner-Schmidt and Duman, 2007;
Greene et al., 2009; Elsayed et al., 2012). This loss of trophic sup-
port to neuronal structure and function results in shrinkage of the
dendritic tree of hippocampal neurons (Sousa et al., 2000; Bessa
et al., 2009), and ultimately, loss of granule cells (Jayatissa et al.,
2008, 2010). Another relevant factor is that the hippocampus is
one of very few brain areas in which neurogenesis continues into
adult life, and this process is powerfully suppressed by prolonged
exposure to corticosterone or to stressors (Wong and Herbert,
2004; Samuels and Hen, 2011; Petrik et al., 2012), including CMS
(Mineur et al., 2007; Oomen et al., 2007). These morphological
changes are associated with a decrease in the volume of the hip-
pocampus following CMS (Bessa et al., 2009; Delgado y Palacios
et al., 2011), which is the major abnormality reported in struc-
tural imaging studies of patients with major depression (Campbell
et al., 2004; Videbech and Ravnkilde, 2004). As a consequence of
these neurotoxic effects, the outputs of the hippocampus are
compromised. The hippocampal inhibitory control of the HPA axis
is exerted via multisynaptic pathways projecting from the sub-
iculum to the paraventricular nucleus of the hypothalamus, via the
stria terminalis, the lateral septum, and other hypothalamic nuclei
(Herman et al., 2005; Belzung and Billette de Villemeur, 2010). In all
these structures, changes in neuronal activity secondary to gluco-
corticoid stimulation of hippocampal neurons were absent in ani-
mals subjected to CMS (Surget et al., 2011).
While the hippocampus is the brain area that is most sensitive
to the neurotoxic effects of stress, prolonged exposure to stress or
high levels of glucocorticoids can also cause damage in many other
brain regions, particularly the prefrontal cortex (PFC) (Liu and
Aghajanian, 2008; Hinwood et al., 2011; McEwen, 2010; Dias-
Ferreira et al., 2009), which, like the hippocampus, also exercisesPlease cite this article in press as: Willner, P., The chronic mild stress (CMS
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2009; Jankord and Herman, 2008). Consistent with these effects
in other stress models, CMS causes atrophy of dendrites on pyra-
midal cells in the medial PFC (Bessa et al., 2009; Licznerski and
Duman, 2013), associated with decreases in prefrontal meta-
bolism (Caldecott-Hazard et al., 1988) and burst ﬁring of pyramidal
cells (Guo et al., 2014), and decreased expression of BDNF (Guo
et al., 2014; Filho et al., 2015) and synaptic proteins such as
PSD95, synapsin I and connexion 43 (Li et al., 2011b; Chen et al.,
2016), together with loss of glial cells (Banasr and Duman, 2008;
Elsayed et al., 2012) and a decrease in the volume of the PFC
(Bessa et al., 2009).
The amygdala is the point of entry through which stress stim-
ulates the HPA axis. In contrast to the negative feedback of the HPA
axis that operates primarily through the hippocampus (and, to a
lesser extent, the PFC), a positive feedback system operates through
the amygdala, such that activation of the amygdala by stress
stimulates the HPA axis, which in turn further stimulates the
amygdala, the system being held in check by the hippocampus
(Myers et al., 2012). Consequently, a loss of hippocampal inhibition
over the HPA axis increases activity in the amygdala. CMS has been
found to cause an increased coherence of activity in the amygdala
(Delgado y Palacios et al., 2014), along with an increase in the
length of dendrites and the density of dendritic spines (Li et al.,
2015; Sharma and Thakur, 2015; Qiao et al., 2016), and increased
expression of CRF (associated with anxiogenesis) and synaptic
proteins (Wang et al., 2010; Li et al., 2015). This increased amyg-
dalar activity in turn has consequences for activity in remote brain
areas. Of particular interest, activation of the amygdala by CMS
causes a decrease in the activity of mesolimbic dopamine cells in
the ventral tegmental area (VTA) (Chang and Grace, 2014). The
mesolimbic dopamine system has long been of interest in relation
to the anhedonic effects of CMS. In particular, CMS has been shown
to decrease the release of dopamine in the nucleus accumbens shell
in response to reward, while at the same time increasing dopamine
release in the same region in response to aversive stimulation (Di
Chiara et al., 1999), and to decrease the expression of dopamine
D2 receptors in the nucleus accumbens (Papp et al., 1994;
Dziedzicka-Wasylewska et al., 1997). Drugs that activate the mes-
olimbic dopamine system reverse CMS-induced anhedonia
(Willner et al., 1994; Papp andWieronska, 2000), an effect also seen
with optogenetic activation of the VTA (Tye et al., 2013). The effect
of CMS is transmitted from the amygdala to the VTAvia a projection
involving the ventral pallidum (Chang and Grace, 2014), which in
turn projects to the VTA via the lateral habenula and rostromedial
tegmental nucleus (Hikosaka, 2010; Proulx et al., 2014). (A similar
amygdala e habenula e VTA pathway has been delineated in the
human brain: Ide and Li, 2011.) The lateral habenula is recognized
to be a key structure mediating the response to emotionally
negative states, via control of the ascending 5HT and mesolimbic
dopamine pathways (Hikosaka, 2010; Proulx et al., 2014). Consis-
tent with the effects already described in the amygdala and the
mesolimbic system, CMS increases metabolic activity in the habe-
nula (Caldecott-Hazard et al., 1988), and inhibition of this area by
deep brain stimulation reverses the behavioural sequelae of CMS
(Meng et al., 2011; Lim et al., 2015).
It is evident that CMS inﬂuences multiple brain systems, and
that the mesolimbic dopamine system, which has been most
closely associated with the anhedonic effects of CMS, is affected by
CMS via a very indirect route (amygdala e ventral pallidum e
lateral habenula e rostromedial tegmental nucleus e VTA e nu-
cleus accumbens). This is perhaps relevant to the observation that
decreases in sucrose intake may be more limited (e.g. Henningsen
et al., 2009; Strekalova and Steinbusch, 2010) or more difﬁcult to
detect (see Willner, 2016) than certain other effects of CMS that) model of depression: History, evaluation and usage, Neurobiology of
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9. Mechanisms of antidepressant action in the CMS model
Any analysis of antidepressant action must start with the
observation that the canonical action of antidepressants, to in-
crease transmission at monoaminergic synapses by blocking the
reuptake of 5HT and NA, is indeed the basis of their clinical action.
While many alternative mechanisms have been proposed in recent
years, this basic observationwas established many years ago by the
classic clinical observations of Delgado and colleagues that,
following successful antidepressant treatment of depression, the
effect in patients treated with speciﬁc 5HT reuptake inhibitors
(SSRIs) is reversed by a dietary intervention that decreases trans-
mission at 5HT synapses (Delgado et al., 1990, 1999), while the ef-
fect in patients treated with speciﬁc NA reuptake inhibitors (NRIs)
is blocked by a pharmacological intervention that decreases
transmission at catecholaminergic synapses (Delgado et al., 1993;
Miller et al., 1996). Similar effects have been reported in the CMS
model: chronic treatment with the SSRI citalopram and the NRI
desipramine reversed cognitive impairments in animals subjected
to CMS, which were in turn blocked by acute antagonism of
transmission at 5HTand NA synapses, respectively (Furr et al., 2011;
Bondi et al., 2010).
As outlined above, and elsewhere (Hill et al., 2012;Willner et al.,
2013, 2014), CMS has a multitude of neurobiological effects, and
almost all are reversed by chronic antidepressant treatment. The
question, then, is which of those many effects are located within
critical pathways from the synapse to behavioural or clinical re-
covery? As the studies of antagonism of antidepressant effects at
5HT and NA synapses so powerfully demonstrate, this question can
be answered by techniques that antagonise speciﬁc components of
the spectrum of antidepressant effects. This approach was ﬁrst
applied to the CMS model in the context of dopaminergic effects of
antidepressant drugs. After chronic treatment, antidepressants of
all classes increase the expression and functional sensitivity of D2
DA receptors in the nucleus accumbens (Papp et al., 1994;
Dziedzicka-Wasylewska et al., 1997), the terminal integrative area
of the mesolimbic DA system (a speciﬁc effect that is not seen in
other brain regions). The functional signiﬁcance of this effect was
conﬁrmed in a series of studies showing that the recovery from
CMS-induced anhedonia following antidepressant treatment was
reversed by an acute challenge with low doses of D2 receptor-
blocking drugs, which reversed the action of SSRI, NRI or mixed
5HT-NA uptake inhibitors, while having no effect in non-stressed or
non-antidepressant-treated animals (Muscat et al., 1990, 1992;
Sampson et al., 1991). As antidepressants do not affect DA uptake
(other than a transitory effect in the PFC, where DA is cleared from
synapses primarily by the NA transporter: Tanda et al., 1996), the
DA-antidepressant interaction probably occurs indirectly: the
ascending 5HT and NA projections terminate within the hippo-
campus, amygdala and PFC, all of which project to the nucleus
accumbens shell, where their projections terminate in partially
overlapping ﬁelds (French and Totterdell, 2002, 2003), and on the
same cells that also receive a dopaminergic innervation (Sesack and
Grace, 2010). Signiﬁcantly, like the effects of 5HT and NA synthesis
blockade described above, the effect of D2 receptor blockade is also
seen in patients: as predicted from the CMS studies, administration
of a low dose of the D2 antagonist sulpiride caused a profound
return of depressed mood in depressed patients successfully
treated with SSRIs (Willner et al., 2005).
The mechanisms by which the primary effect of antidepressant
drugs, increased transmission at monoaminergic synapses, gives
rise to behavioural changes that may emanate from distant brain
areas is now reasonably well understood, and mirrors in large partPlease cite this article in press as: Willner, P., The chronic mild stress (CMS
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neurotoxic effects of stress. As summarized in Fig. 3, and described
below, through actions at 5HT1A/5HT2B and noradrenergic re-
ceptors, antidepressants inﬂuence intracellular second messengers
and protein kinases, leading to increased expression of CREB, which
in turn increases the expression of BDNF and other neurotrophins
that stimulate neurogenesis in the hippocampus and synapto-
genesis in the hippocampus and PFC, leading to repair of damaged
projections and a rebalancing of information processing in the
forebrain. Much of this account can be supplemented by evidence
from other animal models (Willner et al., 2013, 2014), but CMS
studies alone provide a comprehensive picture. (The CMS model
may be unique in this respect.)
A critical role of adult hippocampal neurogenesis was ﬁrst
described in the classic study of Santarelli et al. (2003): following a
blockade of cell division by X-irradiation of the mouse hippocam-
pus, the SSRI ﬂuoxetine no longer reversed the behavioural effects
of CMS, an observation subsequently extended to the tricyclic an-
tidepressant imipramine (Surget et al., 2008). The same treatment
also prevented the restoration of activity in brain areas towhich the
hippocampus projects, as well as the normalization of the HPA axis
(Surget et al., 2011). Through shielding, X-irradiation was conﬁned
to the HPC, and blockade of neurogenesis in the other major site of
adult neurogenesis, the subventricular zone, was without effect,
conﬁrming the crucial role of the HPC (Santarelli et al., 2003).
Neurogenesis is under the control of neurotrophins: hippocampal
infusions of SU5416, an antagonist of the receptor for the neuro-
trophin vascular endothelial growth factor (VEGF), also blocked cell
proliferation and survival of immature neurons, as well as the
restoration of hedonic reactivity, in antidepressant-treated CMS
animals (Warner-Schmidt and Duman, 2007; Greene et al., 2009).
The signiﬁcance of neurogenesis in antidepressant action has been
criticized (Hanson et al., 2011), a major issue being that suppression
of neurogenesis by the toxin methylazoxymethanol acetate (MAM)
failed to block the anti-anhedonic effect of a range of antidepres-
sants (Bessa et al., 2009). However, a subsequent study showed that
this is a matter of timing: MAM did block antidepressant effects in
the CMSmodel if administered several weeks before the test, which
corresponds to the timing used in X-irradiation studies, and sug-
gests that the critical factor is not the genesis of newcells per se, but
rather their maturation and incorporation into functional circuits
(Mateus-Pinheiro et al., 2013). It appears, therefore, that neuro-
genesis may be essential for the maintenance of antidepressant
effects in the CMS model, but perhaps not for their initiation.
Perhaps more important than neurogenesis for the early stages
of recovery from CMS is the effect of synaptogenesis. Antidepres-
sants, both monoamine uptake inhibitors and MAO-A inhibitors,
restore the atrophied dendritic tree of hippocampal neurons in
animals subjected to CMS (Sousa et al., 2000; Luo and Tan, 2001;
Bessa et al., 2009; Licznerski and Duman, 2013; Morais et al.,
2014). This effect is associated with a recovery of synaptic func-
tion (Kallarackal et al., 2013) and a restoration of hippocampal
volume (Bessa et al., 2009; Kong et al., 2009). Neuronal growth is
promoted by BDNF and other neurotrophins and behavioural re-
sponses to chronic antidepressant treatment (in other experi-
mental models) are blocked in mutant mice with full or forebrain-
speciﬁc impairment of either BDNF or its receptor, TrkB
(Saarelainen et al., 2003; Monteggia et al., 2004), or by a region-
speciﬁc knockdown of BDNF in the dentate gyrus or ventral sub-
iculum of the hippocampus (but not in the CA1 or CA3 ﬁelds)
(Adachi et al., 2008; Taliaz et al., 2010). Consistent with these ob-
servations in other models, behavioural recovery in the CMS model
was also blocked by knockdown of BDNF (Ibarguen-Vargas et al.,
2009) or by a TrkB inhibitor (Li et al., 2011a; Yi et al., 2014; Mao
et al., 2014; Luo et al., 2015).) model of depression: History, evaluation and usage, Neurobiology of
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VEGF, and other neurotrophins, is controlled by the nuclear tran-
scription factor CREB. The expression of CREB in the hippocampus
is increased by chronic, but not acute administration of antide-
pressants of all classes (Nibuya et al., 1995; Duman and Monteggia,
2006; Martinowich et al., 2007). In an important CMS study by
Kong et al. (2009), the ability of chronic ﬂuoxetine treatment to
reinstate CREB phosphorylation was blocked in mice with a
knockout of the water channel protein AQP4, which also failed to
show other effects of chronic ﬂuoxetine downstream from CREB,
including stimulation of neurogenesis and reversal of anhedonic
and other behavioural effects of CMS. This study also clariﬁed the
upstream pathway from synaptic receptors to CREB. CREB activity is
under the control of several second messenger systems, including
phosphokinase A and C (PKA, PKC), extracellular signal-related ki-
nases (ERK1/2) and calcium/calmodulin-dependent protein kinase
IV (CaMKIV). In the AQP4 knockout animals, CMS and ﬂuoxetine
had no effect on PKC activity; PKA and ERK1/2 activities were
decreased by CMS and reinstated by ﬂuoxetine; but ﬂuoxetine
failed to reverse CMS-induced inhibition of CaMKIV activity, sug-
gesting that this system provides the critical pathway from the
synapse to the nucleus.
With the exception of neurogenesis, which is speciﬁc to the
hippocampus, a similar story is developing in the PFC. For example,
CMS has been shown to decrease glial cell proliferation in the PFC,
which was reinstated by chronic antidepressant treatment (Banasr
et al., 2007). The expression of ﬁbroblast growth factor-2 (FGF-2) is
also decreased by CMS in the PFC speciﬁcally, and the effects of
antidepressant treatment to reinstate sucrose consumption and
gliogenesis were blocked by local administration of a FGF receptor
antagonist (Elsayed et al., 2012) or by a toxic ablation of PFC as-
trocytes (Banasr and Duman, 2008). Antidepressants also reme-
diate the dendritic atrophy and spine loss of PFC pyramidal cells in
CMS animals (Bessa et al., 2009; Mateus Pinheiro et al., 2013;
Licznerski and Duman, 2013), with recovery of lost PFC volume
(Bessa et al., 2009) and a restoration of burst ﬁring by pyramidal
neurons, which was suppressed by CMS (Guo et al., 2014). These
effects are associated with e and presumably, driven by e changes
in PFC BDNF expression, which is decreased by CMS and restored by
chronic antidepressant treatment (Guo et al., 2014; Filho et al.,
2015; Jin et al., 2015; Tang et al., 2015b).
The importance of the PFC as a target for antidepressant action is
highlighted by the effectiveness of deep brain stimulation of the
ventromedial PFC in treatment resistant depression (Mayberg,
2009; Hamani et al., 2011), together with the signiﬁcance of the
PFC as the site of antidepressant action of the NMDA receptorPlease cite this article in press as: Willner, P., The chronic mild stress (CMS
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ments in antidepressant refractory patients following a single
intravenous infusion (Berman et al., 2000; Zarate et al., 2006;
Diazgranados et al., 2010). In the CMS model, a single injection of
ketamine caused a rapid reversal, within 2 h, of the anhedonic and
other behavioural effects of CMS. Within 24 h, a single ketamine
injection also reversed the loss of synaptic proteins and atrophy of
dendritic spines in the PFC and the associated electrophysiological
deﬁcits (Li et al., 2010, 2011b; Duman et al., 2012; Tang et al., 2015a).
These effects appear to be mediated by the rapid stimulation by
ketamine of the mammalian target of rapamycin (mTOR), because
they were blocked, in the CMS model, by the selective mTOR in-
hibitor rapamycin (Li et al., 2010, 2011b; Duman et al., 2012). The
mTOR pathway is localized in neuronal dendrites and spines and
contributes to activity-dependent synaptic plasticity via the syn-
thesis of proteins for new synapse formation (Hoeffer and Klann,
2010). The precise mechanism by which ketamine interacts with
mTOR to reverse CMS effects is unclear because ketamine does not
alter mTOR activity (Li et al., 2010, 2011b; Tang et al., 2015a), but it
does decrease the activity of the downstream effectors of mTOR
(Tang et al., 2015a).
The ketamine story has heightened interest in glutamatergic
synapses in the PFC as a potential extra-hippocampal and non-
monoaminergic target for antidepressant action. Antidepressant-
like effects of NMDA antagonists were described in early CMS
studies (Klimek and Papp, 1994; Papp and Moryl, 1994), and more
recent CMS studies have reported rapid antidepressant-like effects,
comparable to those of ketamine, for selective antagonists at the
NMDA-1B subunit (Li et al., 2011b) and the glycine site on the
NMDA receptor (Zhu et al., 2013), as well as a partial agonist at the
glycine site (Burgdorf et al., 2015). Glial cells in the PFC have an
important role in removing glutamate from the extracellular space,
and as noted above, antidepressant action in the CMS model was
blocked by ablation of astrocytes in the PFC (Banasr and Duman,
2008). Consistently, an antidepressant-like effect was seen with
riluzole, which decreases activity at glutamatergic synapses by
decreasing presynaptic release of glutamate and facilitating uptake
by glial cells (Banasr et al., 2010). In contrast to these reports,
antidepressant-like effects in the CMS model have also been re-
ported for an inhibitor of the glycine transporter GlyT1 (Depoortere
et al., 2005), and following epigenetic induction of mGlu2 receptors
(Nasca et al., 2013), two treatments that might be expected to
potentiate glutamatergic transmission at NMDA receptors (Cubelos
et al., 2005; Tyszkiewicz et al., 2004). These discrepancies await
resolution.) model of depression: History, evaluation and usage, Neurobiology of
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The CMS model was originally developed as a platform for
investigating neurobiological mechanisms, as discussed in the two
preceding sections, rather than as a drug discovery vehicle, for
which it is ill-suited by virtue of the long duration and labour-
intensive nature of CMS experiments. Nevertheless, use of the
CMS model has been widely adopted within drug discovery and
development programmes. Analysis of publications retrieved in the
PubMed search (Figs. 1 and 2) suggests that overall around 20% of
CMS publications report studies of potential novel antidepressants,
with an increase since 2010 to 30% in 2015, reﬂecting the growth in
studies involving traditional Chinese medicines (Table 1). From
these ﬁgures it can be estimated that there are more than 300
publications describing the use of the CMS model in a drug
development context. This total excludes studies of conventional
antidepressants, ketamine and brain stimulation, as well as the
many unpublished studies conducted by or on behalf of drug
companies. It is beyond the scope of the present paper to review in
detail this extensive literature, but two general trends are apparent.
The major driver of the search for novel antidepressants has
been the failure over many years to achieve signiﬁcant improve-
ments in efﬁcacy, delay of onset, or proportion of depressed pa-
tients responding to treatment, prompting a search for drugs acting
other than by potentiating transmission at monoaminergic syn-
apses. The growing evidence that antidepressants act by repairing a
damaged hippocampus provided an alternative starting point,
leading to many new approaches aimed at achieving the same end
by different means. These include drugs that act as HPA antagonists
(to decrease the threat to the hippocampus by dampening the
response to stress), neuroprotective agents (to protect the hippo-
campus against glucocorticoid-induced neurotoxicity), or pro-
moters of neurogenesis and synaptogenesis (to repair the damage).
Table 4 lists some HPA-antagonist and neuroprotective agents for
which antidepressant effects have been reported in both CMS and
clinical studies. (It is important to add that some of the clinical
effects listed are far from well established: the table is intended
simply to illustrate the variety of approaches.) The CMS literature
also includes a panoply of further antioxidant and other neuro-
protective agents that have not been tested clinically. However,
while many drugs have been identiﬁed that have antidepressant
effects and beneﬁcial effects on the hippocampus, there is minimal
evidence that any of them improve on conventional antidepres-
sants in respect of their efﬁcacy, onset of action, or, for the drugs
that have been tested clinically, their effectiveness in treatment-
resistant patients. And this is hardly surprising: conventional an-
tidepressants provide an effective and efﬁcient repair service andTable 4
Antidepressant activity via neuroprotection a.
CMS
HPA inhibitors
CS synthesis inhibition Kvarta et al., 2015
CS receptor antagonism Wu et al., 2007
CRF antagonism Ducottet et al., 2003
Cytokine antagonism Goshen et al., 2008
Oestrogen Romano-Torres and Fern
Anti-oxidants
Omega-3 pufas Vancassel et al., 2008
Ascorbic acid Moretti et al., 2012
S-adenosylmethionine Benelli et al., 1999
Melatonin Haridas et al., 2013
Curcumin Liu et al., 2014
a For each target the table lists a single example from each of the CMS and c
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competitors would do the job better (Willner et al., 2014).
As discussed earlier in this review, and elsewhere (Willner et al.,
2013, 2014), stress-induced hippocampal damage leads to changes
in the functioning of distant brain regions that are more directly
involved in depressive psychopathology. Accordingly, an alterna-
tive strategy is to consider targets outside the hippocampus. Table 5
lists interventions for which antidepressant efﬁcacy has been re-
ported, in both CMS experiments and clinical trials, through actions
at extra-hippocampal sites (and not directly involving potentiation
of NA or 5HT transmission). For each intervention, the table lists a
single clinical reference (for all except the ﬁnal three entries there is
an extensive clinical literature) as well as studies reporting
antidepressant-like actions in the CMS model. The interventions
include the use of deep brain stimulation to inhibit activity in not
only the ventromedial prefrontal cortex, but also the lateral habe-
nula, ventral tegmental area andmedial forebrain bundle, as well as
activation of the dorsolateral prefrontal cortex by repeated trans-
cranial magnetic stimulation (rTMS). The melatonin MT1/MT2
agonist and 5-HT2C antagonist agomelatine is one of very few
agents with greater efﬁcacy than other antidepressants: the site of
action of agomelatine is unknown, but the lateral habenula is a
strong candidate (Willner et al., 2013). Antidepressant effects are
also reported for drugs that potentiate activity in the mesolimbic
dopamine system, through presynaptic or postsynaptic actions
(atypical antipsychotics and D2/3 agonists, respectively). The ﬁnal
entries in the table are drugs targeting the glutamate system,
which, as discussed above, include, in addition to ketamine, the
glutamate release inhibitor riluzole, the mGlu2 enhancer l-ace-
tylcarnitine, and the glycine receptor partial agonist rapastinel. In
some cases the CMS experiments were conducted to corroborate
clinical observations, while in others, the CMS studies were part of
the developmental trajectory preceding the clinical trials.
Of particular signiﬁcance, most of the interventions listed in
Table 5 are claimed to act more rapidly than conventional antide-
pressants, and with a single exception (agomelatine), all of them
are claimed to be effective in treatment-resistant depression. (The
clinical studies cited in Table 5 were chosen to illustrate this point.)
Indeed, for ethical reasons, most of these interventions (agomela-
tine, the dopaminergic drugs and rTMS are exceptions), have only
been tested in patients who failed to respond to antidepressant
treatment. In commonwith other animal models of depression, the
CMS model can report that a novel intervention is antidepressant-
like, but, because the model responds to conventional antidepres-
sants, it cannot predict whether a novel intervention will also be
effective in patients who are treatment-resistant. Consequently,
while CMS may be an excellent model for studying problemsDepression
Kling et al., 2009
Gallagher et al., 2008
Zobel et al., 2000
Raison et al., 2013
andez-Guasti, 2010 Keating et al., 2011
Sarris et al., 2016
Amr et al., 2013
Sarris et al., 2016
Fava et al., 2012
Sanmukhani et al., 2014
linical literatures.
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Table 5
Extra-hippocampal sites of antidepressant action a.
Brain site Treatment CMS Depression
Lateral habenula Deep brain stimulation Lim et al., 2015 Sartorius et al., 2010
Agomelatine? Papp et al., 2003; Boulle et al., 2014; Rossetti et al., 2016 Taylor et al., 2014
Ventral tegmental area DA D2 antagonists Papp and Wieronska, 2000 Kriston et al., 2014
Nucleus accumbens DA D2 agonists Willner et al., 1994 Lattanzi et al., 2002
Deep brain stimulation Gersner et al., 2010 Bewernick et al., 2012
Medial forebrain bundle Deep brain stimulation Furlanetti et al., 2015 Galvez et al., 2015
dl-Prefrontal cortex Repeated transcranial magnetic stimulation Feng et al., 2012; Wang et al., 2014; Kim et al., 2014 Rossini et al., 2005
vm-Prefrontal cortex Deep brain stimulation Hamani et al., 2012; Lim et al., 2015; Dournes et al., 2013 Mayberg, 2009
Ketamine Li et al., 2010, and many other papers Coyle and Laws, 2015
Riluzole Banasr et al., 2010 Zarate et al., 2004
L-acetylcarnitine Nasca et al., 2013 Bersani et al., 2013
Rapastinel Burgdorf et al., 2015 Preskorn et al., 2015
a For each target, the table lists CMS studies and provides a single example from the clinical literature.
P. Willner / Neurobiology of Stress xxx (2016) 1e16 11relevant to depressive features that can be treated with conven-
tional antidepressants, it is less than ideal as a tool for investigating
the speciﬁc features of treatment-resistant depression. A solution
to this problem may be to implement the model in treatment-
resistant animals. This strategy is discussed in detail elsewhere
(Willner and Belzung, 2015): its feasibility has been demonstrated
(Dournes et al., 2013), and further studies along these lines are to be
expected.
One ﬁnal point worth making is that the chronic time-course of
CMS experiments makes it possible to distinguish between anxio-
lytic and antidepressant drugs. Anxiolytics act by dampening acti-
vation of the amygdala (Forster et al., 2012), and consequently,
anxiolytic drugs prevent CMS effects when administered from the
onset of CMS (e.g. Zhao et al., 2012). However, unlike antidepres-
sants, anxiolytics fail to reverse established CMS effects when drug
treatment commences after several weeks of CMS and CMS re-
mains in operation alongside drug treatment (e.g. Muscat et al.,
1992). Consequently, antidepressant activity cannot be inferred
from experiments in which drug treatment and CMS start concur-
rently. While this procedure can decrease the duration of a CMS
experiment by several weeks, it should not be used in studies of the
potential antidepressant activity of novel compounds.11. Conclusions
After a slightly rocky start, the CMS model has become ﬁrmly
established as an indispensable experimental tool for studying the
neurobiological basis of depression. Recent research has added
further to the validity of the model, and early concerns about its
reliability appear to have largely receded. The model has made
substantial contributions to our understanding of the neurobio-
logical consequences of chronic stress and the reversal and repair of
those effects by chronic antidepressant treatment. It is also evident
that the CMS model has become established as a valuable compo-
nent of antidepressant drug discovery and development pro-
grammes. Of course, there is much more to say about these
problems: the aim of this review was identify some speciﬁc con-
tributions of CMS research, not to present a comprehensive account
of the neurobiology of depression and antidepressant action (see
Hill et al., 2012; Willner et al., 2013, 2014), and certainly not to
dismiss other experimental approaches. But for those issues that
have been addressed, the high translational potential of the CMS
model provides grounds for optimism that the positions outlined
here, with respect to neurobiological mechanisms underlying the
chronic effects of stress and antidepressants in rodents, also
describe processes of relevance to human depression and mecha-
nisms of clinical antidepressant action.Please cite this article in press as: Willner, P., The chronic mild stress (CMS
Stress (2016), http://dx.doi.org/10.1016/j.ynstr.2016.08.002Acknowledgements
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